References
B. E. Kreger, D. E. Craven, P. C. Carling and W. R. McCabe,Gram-negative bacteremia. Reassessment of etiology, epidemiology and ecology in 612 patients. Am. J. Med.68, 332–343 (1980).
J. J. Zimmerman and K. A. Dietrich,Current perspectives on septic shock. Pediatr. Clin. North Am.34, 131–163 (1987).
C. L. Sprung, P. V. Caralis, E. H. Marcial et al.,The effects of high-dose corticosteroids in patients with septic shock. N. Engl. J. Med.311, 1137–1143 (1984).
K. J. Tracey, B. Beutler, S. F. Lowry, J. Merryweather et al.,Shock and tissue injury induced by recombinant human cachectin. Science234, 470–474 (1986).
M. F. Wilson and D. J. Brackett,Release of vasoactive hormones and circulatory changes in shock. Circ. Shock11, 225–234 (1983).
A. M. Lefer,Eicosanoids as mediators of ischemia and shock. Federation Proc.44, 275–280 (1985).
P. Vadas, S. Wasi, H. Movat and J. Hay,Extracellular phospholipase A 2 mediates inflammatory hyperemia. Nature273, 583–585 (1981).
P. Vadas and J. Hay,The appearance and significance of phospholipase A 2 in lymph draining tuberculin reactions. Am. J. Pathol.107, 285–291 (1982).
P. Vadas and W. Pruzanski,Role of extracellular phospholipase A 2 in inflammation. Adv. Inflamm. Res.7, 51–59 (1984).
R. Franson, R. Dobrow, J. Weiss, P. Elsbach and W. B. Weglicki,Isolation and characterization of a phospholipase A 2 from an inflammatory exudate. J. Lipid Res.19, 18–23 (1978).
W. Pruzanski, P. Vadas, E. Stefanski and M. B. Urowitz,Phospholipase A 2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis: its possible role as a proinflammatory enzyme. J. Rheumatol.12, 211–216 (1986).
P. Vadas, E. Stefanski and W. Pruzanski,Characterization of extracellular phospholipase A 2 in rheumatoid synovial fluid. Life Sci.36, 579–587 (1985).
E. Stefanski, W. Pruzanski, B. Sternby and P. Vadas,Purification of a soluble phospholipase A 2 from synovial fluid in rheumatoid arthritis. J. Biochem.100, 1297–1303 (1986).
W. Pruzanski, E. Keystone and P. Vadas,Serum phospholipase A 2 levels correlate with disease activity in rheumatoid arthritis. Clin. Exp. Immunol., (submitted).
P. Vadas,The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A 2 activity. Life Sci.30, 155–162 (1982).
P. Vadas, W. Pruzanski, A. Sos, A. Melcher, H. Jacobs and T. Cheong,Synthesis and secretion of soluble phospholipase A 2 from cultured osteoblasts. Arthr. Rheum.30, (suppl), S65 (1987).
J. Chang, S. Gilman and A. Lewis,Interleukin 1 activates phospholipase A 2 in rabbit chondrocytes: a possible signal for IL-1 action. J. Immunol.136, 1283–1287 (1986).
W. Pruzanski, P. Vadas and V. Fornasier,Inflammatory effect of intradermal administration of soluble phospholipase A 2 in rabbits. J. Invest. Dermatol.86, 380–383 (1986).
P. Vadas and J. Hay,Secretion of a hyperemia-inducing moiety by mitogen or glycogen-stimulated mononuclear inflammatory cells of sheep and rabbit. Int. Arch. Allergy appl. Immunol.62 142–151 (1980).
P. Vadas and J. Hay.Cutaneous blood flow measurements: a standardization of the microsphere assay for yasocative agents. Agents and Actions8, 504–508 (1978).
H. Shubin and M.-H. Weil,Bacterial shock, JAMA235, 421–424 (1976).
B. Urbaschek and R. Urbaschek,The inflammatory response of endotoxins. Bibl. Ant.17, 74–104 (1979).
P. Vadas and J. Hay,Invovlement of circulating phospholipase A 2 in the pathogenesis of hemodynamic changes in endotoxin shock. Can. J. Physiol. Pharmacol.61, 561–566 (1983).
M. Hallman, R. Spragg, J. H. Harrell, K. M. Moser and L. Gluck,Evidence of lung surfactant abnormality in respiratory failure. J. Clin. Invest.70, 673–683 (1982).
P. Vadas,Elevated plasma phospholipase A 2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med.104, 873–881 (1984).
P. Vadas, W. Pruzanski, E. Stefanski, B. Sternby, R. Mustard, J. Bohnen, I. Fraser, V. Farewell and C. Bombardier,The pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A 2 levels with circulatory collapse. Critical Care Med., in press.
P. Vadas and W. Pruzanski,Role of secretory phospholipases A 2 in the pathobiology of disease. Laboratory Invest.55, 391–404 (1986).
R. Flower,Macrocortin and the antiphospholipase proteins. Adv. Inflam. Res.8, 1–34 (1984).
P. Vadas, W. Pruzanski, E. Stefanski, J. Ruse, V. Farewell, J. McLaughlin and C. Bombardier,Concordance of endogenous cortisol and phospholipase A 2 levels in gram-negative septic shock, A prospective study. J. Lab. Clin. Med., in press.
P. McCullagh,Regression models for orindal data. J. Royal Statistical Society.142, 109–142 (1980).
P. Vadas, E. Stefanski and W. Pruzanski,Comparative analysis of assays for phospholipase A 2 activity using biomembrane associated and micellar substrates. The influence of albumin. Inflammation10, 183–193 (1986).
P. Vadas, E. Stefanski and W. Pruzanski,Potential therapeutic efficacy of inhibitors of human phospholipase A 2 in septic shock. Agents and Actions19, 194–202 (1986).
J. A. Vick and R. B. Brooks,Pharmacological studies of the major fractions of bee venom. Am. Bee J.112, 288–289 (1972).
E. Hebermann,Beiträge zur pharmacologie von phospholipase. A. Arch. Exp. Pathol. Pharmakol.230, 538–546 (1957).
N. A. Marsh and B. C. Whaler,The effects of honey bee venom and two of its constituents, melittin and phospholipase A 2,on the cardiovascular system of the rat. Toxicon,18, 427–435 (1980).
K. M. M. Shakir, J. T. O'Brian and S. L. Gartner,Enhanced phospholipase A 2 activity in rat plasma, liver and intestinal mucosa following endotoxin treatment: possible explanation for the protective effect of indomethacin in endotoxic shock. Metabolism34, 176–182 (1985).
D. Schmidt and G. E. Hoffmann,Activity of phospholipase A compared in serum of patients with pancreatic and nonpancreatic diseases. Clin. Chem.33, 594–596 (1987).
J. T. Flynn, J. M. Henry and W. Perkoswki,Phospholipase A 2 stimulated release of prostanoids from the isolated perfused rabbit liver: implications in regional cellular injury. Can. J. Physiol. Pharmacol.59, 1268–1273 (1981).
H. C. Huang,Effects of phospholipases A 2 from Vipera russelli snake venom on blood pressure, plasma prostacyclin level, and renin activity in rats. Toxicon22, 253–264 (1984).
C. L. Ho and C. Y. Lee,Cardiovascular effects of phospholipases A 2 purified from various snake venoms. Proc. Natl. Sci. Counc. B. ROC5, 181–189 (1981).
H. C. Huang,Release of slow-reacting substance from the guinea-pig lung by phospholipases A 2 of Vipera russelli snake venom. Toxicon22, 359–372 (1984).
F. Hirata, E. Schiffman, K. Venkatasubramanian, D. Solmon and J. Axelrod,A phospholipase A 2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc. Natl. Acad. Sci. USA77, 2533–2536 (1980).
G. J. Blackwell, R. Carnuccio, M. DiRosa, R. J. Flower, C. S. J. Langham, L. Parente, P. Persico, N.-C. Russell-Smith and D. StoneGlucocorticoids induced the formation and release of anti-inflammatory and anti-phospholipase proteins into the peritoneal cavity of the rat. Br. J. Pharmacol.76, 185–195 (1982).
Author information
Authors and Affiliations
Additional information
Supported by The Arthritis Society and The Wellesley Hospital Research Institute.
Rights and permissions
About this article
Cite this article
Vadas, P., Pruzanski, W. & Stefanski, E. Extracellular phospholipase A2: causative agent in circulatory collapse of septic shock?. Agents and Actions 24, 320–325 (1988). https://doi.org/10.1007/BF02028289
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02028289